Vaccine development company receives European patent allowance for enhanced immune response.
Upon receiving the notification Dr. Warwick Kimmins, President and CEO stated, "The issuance of the European patent complements the US patent protection for our VacciMax vaccine platform technology and is good news for IVT's shareholders and our industry partners."
IVT is best known for its proprietary vaccine enhancement platform, VacciMax. The company has significantly advanced the technology since the company was founded in 2000 by Dr. Kimmins, a former Dalhousie University (Halifax, Canada) Dean of Science. IVT's first product was SpayVac, a contraceptive vaccine effective in many animals. According to Dr. Kimmins, the logical next step for the development of the VacciMax platform was in the area of infectious diseases and cancer.
IVT is currently focused developing its VacciMax platform, through licensing the technology to partner companies, both mid to large size, in the animal and human health sectors.
ImmunoVaccine is a life sciences company focused on commercializing a proprietary vaccine platform, trade named VacciMax. The VacciMax platform results in a more rapid immune response with a higher level and longer duration of antibody levels following a single inoculation while providing multi-year protection without boosting. This patented technology is available under license to reformulate existing commercial vaccines and in support of newly developed vaccines for human and veterinary applications.
ImmunoVaccine Technologies, Inc.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Sep 1, 2005|
|Previous Article:||Sirna granted patent covering RNAi-mediated inhibition of gene expression.|
|Next Article:||Genetic mutations in brain tumors identified by scientists from Venter Institute, Ludwig Institute, and Johns Hopkins.|